A Comprehensive Review of Antimicrobial Peptides and Smart Biomaterials in Chronic Wound Therapy: Overcoming Biofilms, Resistance, and Translational Barriers
Authors:
- Laura MaghiarLaura Maghiar
- Paula Bianca MaghiarPaula Bianca Maghiar
- Ovidiu PopOvidiu Pop
- Anca Maria MitranAMAnca Maria Mitran
- Mihaela Mirela MuresanMMMihaela Mirela Muresan
- Andreea-Adriana NeamțuANAndreea-Adriana Neamțu
- Dan IliescuDIDan Iliescu
- Dan BrebuDBDan Brebu
- Paul Andrei TentPaul Andrei Tent
- Florian Dorel BodogFBFlorian Dorel Bodog
- Valentin-Cristian IovinVIValentin-Cristian Iovin
- Cristina DumitrescuCDCristina Dumitrescu
Open Access
- 2 July 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5955
Abstract
Chronic wounds represent a growing global healthcare burden driven by persistent inflammation, polymicrobial biofilm formation, impaired tissue regeneration, and increased antimicrobial resistance. This review examines the mechanistic interplay between chronic wound pathophysiology, biofilm persistence, and antimicrobial peptide (AMP)-based therapeutics, with particular emphasis on translational barriers and advanced biomaterial-enabled delivery strategies. Current evidence demonstrates that AMPs exert multifactorial activities extending beyond direct antimicrobial effects, including membrane disruption, quorum-sensing inhibition, extracellular polymeric substance (EPS) destabilization, immune modulation, angiogenic stimulation, and promotion of re-epithelialization. However, their clinical translation remains limited due to proteolytic degradation, poor stability, cytotoxicity, rapid clearance, and inadequate retention within the hostile chronic wound microenvironment. To address these limitations, emerging biomaterial platforms—including hydrogels, electrospun nanofibers, nanoparticles, self-assembling peptide systems, and stimuli-responsive smart dressings—have been developed to improve AMP stability, controlled release, biofilm penetration, and regenerative efficacy. This review further highlights current preclinical and clinical challenges, including the lack of standardized polymicrobial biofilm models and translationally relevant wound systems, while discussing future perspectives such as artificial intelligence-assisted peptide design and precision wound therapeutics. We argue that peptide discovery is no longer the principal bottleneck: the rate-limiting steps are now peptide stabilization, biofilm-targeted delivery, and dosing, and no current platform yet couples validated eradication of mature polymicrobial biofilms with validated tissue regeneration in a clinically representative model. Collectively, AMP-enabled smart biomaterials may support the transition from passive wound management toward responsive, biofilm-targeted regenerative therapy.Keywords
This publication has 183 references indexed in Scilit:
- Diabetic Wound Repair: From Mechanism to Therapeutic OpportunitiesMedcomm, 2025
- Antimicrobial Peptides: A Promising Alternative to Conventional Antimicrobials for Combating Polymicrobial BiofilmsAdvanced Science, 2024
- Biofilm matrix: a multifaceted layer of biomolecules and a defensive barrier against antimicrobialsArchives of Microbiology, 2024
- Ultrasound‐Responsive HBD Peptide Hydrogel with Antibiofilm Capability for Fast Diabetic Wound HealingAdvanced Science, 2024
- Gold Nanoparticles and Antimicrobial Peptides: A Novel CombinationChemistrySelect, 2024
- Approaches to Control and Monitor Protease Levels in Chronic WoundsAdvanced Therapeutics, 2024
- IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes‐related foot infections (IWGDF/IDSA 2023)Diabetes/Metabolism Research and Reviews, 2023
- Diabetic Foot UlcersJAMA, 2023
- The role of extracellular DNA in the formation, architecture, stability, and treatment of bacterial biofilmsBiotechnology and Bioengineering, 2021
- Platelets and Their Interactions with Other Immune CellsComprehensive Physiology, 2015